Immunotherapy maker TxCell SA has appointed gene therapy expert Olivier Danos to its newly founded Scientific Advisory Board. Danos serves as Senior Vice President of Cell and Gene Therapy at Biogen and has led Biogen’s gene therapy research group for the last two years. Previously, Danos served as Senior VP Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals.
EC delays bioeconomy strategy review
Latest NewsThe fate of the bioeconomy in Europe remains undecided. The evaluation of the European Commission’s bioeconomy strategy plus action plan has been delayed.
Apeiron licences neuroblastoma antibody
Latest NewsAustrian Apeiron Biologics has outlicensed the global marketing rights for its neuroblastoma antibody dinutuximab beta to British Eusa Pharma.
Diabetes giant cuts jobs
Latest NewsDanish insulin maker Novo Nordisk tries to relieve financial pressure by laying off 1,000 staff. The step was necessary due to challenges on the US market, the company said.
Immunicum: Doctor takes the lead
AppointmentsSwedish immuno-oncology play Immunicum AB has appointed Carlos de Sousa as its new CEO. Most recently, de Sousa worked as Chief Business Offer at Danish Zealand Pharma.
Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies
Sponsored PublicationsHumanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.
Bluebird bio selects Medigene for TCR development
Latest NewsCAR T cell specialist bluebird bio has inked a potential US$1bn partnership with Medigene – to get access to the drug developer’s technology platform.
TxCell: Board ahoy
AppointmentsImmunotherapy maker TxCell SA has appointed gene therapy expert Olivier Danos to its newly founded Scientific Advisory Board. Danos serves as Senior Vice President of Cell and Gene Therapy at Biogen and has led Biogen’s gene therapy research group for the last two years. Previously, Danos served as Senior VP Molecular Medicine, Synthetic Biology and Gene Regulation at Kadmon Pharmaceuticals.
IP Flash: Early Certainty boon or bane?
OpinionThe European Patent Office (EPO) is currently pushing the project Early Certainty in order to speed up examination of patent applications. The aim is to complete examination within 12 months between request for examination and intent to grant the application or refusal.
TOP3 CHALLENGES FOR COMMERCIAL TEXT MINERS
Sponsored PublicationsHow Content Access and Manual Process Hinder Mining Efforts
Update: Immunic bags €17.5m
Latest NewsMartinsried-based autoimmune specialist Immunic AG secured financial support for the next 3.5 years from lead investors Life Sciences Partners and LifeCare Partners (LCP, Switzerland) based on prior autoimmune programmes of 4SC AG.